Table of Content

1. Introduction To CD70 Targeting Therapy
1.1 CD70 Targeting Therapy Overview
1.2 The Prerequisite For CD70 Targeting Therapy
1.3 Dual Role of CD70 As Diagnostic & Prognostic Biomarker


2. CD70 Targeting Therapeutic Approaches
2.1 Monoclonal Antibody
2.2 Bispecific Antibody
2.3 Tetraspecific Antibody
2.4 CAR T Cell Therapy
2.5 Antibody Drug Conjugate
2.6 CAR-NK Therapy


3. CD70 Targeting Therapies Clinical Research & Development By Indications
3.1 Leukemia
3.2 Lymphoma
3.3 Gynecologic Cancer
3.4 Renal Cell Carcinoma
3.5 Lung Cancer
3.6 Autoimmune & Inflammatory Disease
3.7 Viral Infections


4. Global CD70 Targeting Therapies Clinical Trials Overview
4.1 By Phase
4.2 By Country
4.3 By Company
4.4 By Indication
4.5 By Priority Status
4.6 Patient Segment


5. CD70 Targeting Therapies Regulatory Designations: Fast Track & Orphan Designation


6. Global CD70 Targeting Therapies Clinical Trials Insight
6.1 Preclinical
6.2 Phase I
6.3 Phase I/II
6.4 Phase II


7. CD70 Targeting Therapies Development Platforms By Company & Technology
7.1 AlloCAR T Platform
7.2 Gamma Delta Cell Platform
7.3 Tailwind Platform
7.4 DARPin Platform
7.5 SIMPLE Antibody Platform
7.6 Potelligent Technology
7.7 Off The Shelf Allogeneic Manufacturing


8. Global CD70 Targeting Therapies Current Market Trend & Developments
8.1 Current Market Outline
8.2 Future Market Forecast


9. CD70 Targeting Therapies Market Opportunity & Clinical Trends By Region
9.1 US
9.2 China
9.3 Europe


10. Combination Strategies For CD70 Targeting Therapies
10.1 In Combination With Immunotherapy
10.2 In Combination With Epigenetic Modulators
10.3 In Combination With Targeted Therapy
10.4 In Combination With Oncolytic Virus Therapy
10.5 In Combination With Chemotherapy


11. Global CD70 Targeting Therapies Market Dynamics
11.1 Market Drivers
11.2 Market Challenges


12. Competitive Landscape
12.1 Adaptimmune
12.2 Adicet Bio
12.3 Allogene Therapeutics
12.4 Ambrx (Johnson & Johnson)
12.5 Chongqing Precision Biotech
12.6 Chinook Therapeutics (Novartis)
12.7 CRISPR Therapeutics
12.8 ImmuneOnco Biopharma
12.9 Pfizer
12.10 Poseida Therapeutics



List of Figures

Figure 1-1: Introduction To CD70 Protein
Figure 1-2: History & Development Of CD70 Targeting Therapies
Figure 1-3: CD70 As Diagnostic & Prognostic Marker In Cancer

Figure 2-1: Approaches For Targeting CD70

Figure 3-1: Role Of CD70 In Leukemia
Figure 3-2: Molecular Partners – MP0533
Figure 3-3: MP0533 Phase I/II (NCT05673057) Study – Initiation & Completion Year
Figure 3-4: Cusatuzumab Phase II (NCT04023526) Study – Initiation & Completion Year
Figure 3-5: Cusatuzumab Phase II (NCT06384261) Study – Initiation & Completion Year
Figure 3-6: Role Of CD70 In Leukemia
Figure 3-7: CAR.70/IL-15 NK Cell Therapy Phase II (NCT05092451) Study – Initiation & Completion Year
Figure 3-8: CB CAR-NK019 Phase I (NCT05667155) Study – Initiation & Completion Year
Figure 3-9: CD70 CAR T Therapy Early Phase I (NCT04662294) Study – Initiation & Completion Year
Figure 3-10: Lymphoma: Key Market Players Conducting CD70 Clinical Research
Figure 3-11: Role Of CD70 In Gynecologic Cancers
Figure 3-12: CD70 CAR-T Therapy Phase I (NCT06010875) Study – Initiation & Completion Year
Figure 3-13: Anti-hCD70 CAR transduced PBL Phase I/II Study – Initiation & Completion Year
Figure 3-14: CTX131 Phase I (NCT05795595) Study – Initiation & Completion Year
Figure 3-15: Role Of CD70 In Renal Cell Carcinoma
Figure 3-16: Research By Allogene Therapeutics
Figure 3-17: TRAVERSE Phase 1 (NCT04696731) Study – Initiation & Completion Year
Figure 3-18: CTX131 Phase I/II (NCT05795595) Study – Initiation & Completion Year
Figure 3-19: CTX131 Phase I/II (NCT05795595) Study – Initiation & Completion Year
Figure 3-20: Role Of CD70 In Lung Cancer
Figure 3-21: Role Of CD70 In Autoimmune & Inflammatory Diseases
Figure 3-22: Role Of CD70 In Autoimmune & Inflammatory Diseases

Figure 4-1: Global – CD70 Targeting Therapies Clinical Trials By Phase (Numbers), 2025
Figure 4-2: Global – CD70 Targeting Therapies Clinical Trials By Country (Numbers), 2025
Figure 4-3: Global – CD70 Targeting Therapies Clinical Trials By Company (Numbers), 2025
Figure 4-4: Global – CD70 Targeting Therapies Clinical Trials By Indication (Numbers), 2025
Figure 4-5: Global – CD70 Targeting Therapies Clinical Trials By Priority Status (Numbers), 2025
Figure 4-6: Global – CD70 Targeting Therapies Clinical Trials By Patient Segment (Numbers), 2025

Figure 7-1: Allogene Therapeutics - AlloCAR T Platform
Figure 7-2: Adicet Bio - Gamma Delta Cell Platform
Figure 7-3: ADI-270 - CD70 CAR ?? T Cell Therapy
Figure 7-4: Catamaran Bio – Tailwind Platform
Figure 7-5: Molecular Partners - DARPin Platform
Figure 7-6: Nkarta – CAR-NK Cells
Figure 7-7: Nkarta - Proprietary CAR-NK Cells Manufacturing Process

Figure 8-1: CD70 Targeting Therapy Current Market – Guiding Factors
Figure 8-2: Key Players In CD70 Market
Figure 8-3: CD70 Targeting Therapy Market Future - Influencing Factors

Figure 10-1: Combinations Of CD70 Therapy With Other Therapies
Figure 11-1: Global CD70 Targeting Therapy Market - Drivers
Figure 11-2: Global CD70 Targeting Therapy Market – Challenges

List of Tables

Table 6-1: CD70 Targeting Therapies With Regulatory Designations